PsychoGenics Achieves Substantial Milestone in its Drug Discovery Collaboration with Sunovion

November 5, 2012 – Tarrytown, New York. – PsychoGenics today announced that the Food and Drug Administration (FDA) has accepted Sunovion’s IND for SEP360, triggering a milestone payment to PsychoGenics, and that human dosing has been initiated.